Search Results - "Thummel, KE"

Refine Results
  1. 1

    EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM by WEILI HUANG, LIN, Yvonne S, MCCONN, Donavon J, CALAMIA, Justina C, TOTAH, Rheem A, ISOHERRANEN, Nina, GLODOWSKI, Mary, THUMMEL, Kenneth E

    Published in Drug metabolism and disposition (01-12-2004)
    “…CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity but can differ in product regioselectivity and formation activity. To further explore…”
    Get full text
    Journal Article
  2. 2

    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing by Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE, MacPhee, IAM

    Published in Clinical pharmacology and therapeutics (01-07-2015)
    “…Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive…”
    Get full text
    Journal Article
  3. 3

    Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction by Thummel, Kenneth E., Kunze, Kent L., Shen, Danny D.

    Published in Advanced drug delivery reviews (15-09-1997)
    “…Oral bioavailability of pharmacologically effective drugs is often limited by first-pass biotransformation. In humans, both hepatic and intestinal enzymes can…”
    Get full text
    Journal Article
  4. 4

    Fentanyl Metabolism by Human Hepatic and Intestinal Cytochrome P450 3A4: Implications for Interindividual Variability in Disposition, Efficacy, and Drug Interactions by LABROO, R. B, PAINE, M. F, THUMMEL, K. E, KHARASCH, E. D

    Published in Drug metabolism and disposition (01-09-1997)
    “…The synthetic opioid fentanyl undergoes extensive metabolism in humans. Systemic elimination occurs primarily by hepatic metabolism. When administered as a…”
    Get full text
    Journal Article
  5. 5

    Effects of Pregnancy on CYP3A and P-glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study by Hebert, MF, Easterling, TR, Kirby, B, Carr, DB, Buchanan, ML, Rutherford, T, Thummel, KE, Fishbein, DP, Unadkat, JD

    Published in Clinical pharmacology and therapeutics (01-08-2008)
    “…The objectives of the study were to evaluate the effects of pregnancy on CYP3A and P‐glycoprotein (P‐gp) activities, as measured by disposition of midazolam…”
    Get full text
    Journal Article
  6. 6

    Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults by Thummel, Kenneth E., Slattery, John T., Ro, Howard, Chien, Jenny Y., Nelson, Sidney D., Lown, Kenneth E., Watkins, Paul B.

    Published in Clinical pharmacology and therapeutics (01-06-2000)
    “…Background Recent case reports suggest that consumption of ethanol may increase the risk of liver injury induced by acetaminophen (INN, paracetamol). However,…”
    Get full text
    Journal Article
  7. 7

    Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications by Zhang, Y, Zhang, L, Abraham, S, Apparaju, S, Wu, T‐C, Strong, JM, Xiao, S, Atkinson, AJ, Thummel, KE, Leeder, JS, Lee, C, Burckart, GJ, Lesko, LJ, Huang, S‐M

    Published in Clinical pharmacology and therapeutics (01-03-2009)
    “…The US Food and Drug Administration (FDA) is currently developing a guidance for industry to replace a previous guidance, “Pharmacokinetics in Patients With…”
    Get full text
    Journal Article
  8. 8

    Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines by MADANI, S, PAINE, M. F, LEWIS, L, THUMMEL, K. E, SHEN, D. D

    Published in Pharmaceutical research (01-08-1999)
    “…To assess the role of intestinal CYP2D6 in oral first-pass drug clearance by comparing the enzyme content and catalytic activity of a prototype CYP2D6…”
    Get full text
    Journal Article
  9. 9

    Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1 by Thummel, K E, Kharasch, E D, Podoll, T, Kunze, K

    Published in Drug metabolism and disposition (01-03-1993)
    “…The volatile anesthetic agent enflurane undergoes oxidative metabolism in human liver, yielding both inorganic and organic fluoride metabolites. Numerous…”
    Get more information
    Journal Article
  10. 10

    Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose by Rieder, Mark J, Reiner, Alexander P, Gage, Brian F, Nickerson, Deborah A, Eby, Charles S, McLeod, Howard L, Blough, David K, Thummel, Kenneth E, Veenstra, David L, Rettie, Allan E

    Published in The New England journal of medicine (02-06-2005)
    “…The gene encoding vitamin K epoxide reductase complex 1 ( VKORC1 ) is the target of warfarin, and a variant of the gene may be associated with variations in…”
    Get full text
    Journal Article
  11. 11

    Genetic contribution to variable human CYP3A-mediated metabolism by Lamba, Jatinder K, Lin, Yvonne S, Schuetz, Erin G, Thummel, Kenneth E

    Published in Advanced drug delivery reviews (18-11-2002)
    “…The human CYP3A subfamily plays a dominant role in the metabolic elimination of more drugs than any other biotransformation enzyme. CYP3A enzyme is localized…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Evaluation of 6β‐Hydroxycortisol, 6β‐Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo by Peng, C‐C, Templeton, I, Thummel, KE, Davis, C, Kunze, KL, Isoherranen, N

    Published in Clinical pharmacology and therapeutics (01-06-2011)
    “…An endogenous probe for CYP3A activity would be useful for early identification of in vivo cytochrome P450 (CYP) 3A4 inhibitors. The aim of this study was to…”
    Get full text
    Journal Article
  14. 14

    EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO by YANG DAI, HEBERT, Mary F, ISOHERRANEN, Nina, DAVIS, Connie L, MARSH, Christopher, SHEN, Danny D, THUMMEL, Kenneth E

    Published in Drug metabolism and disposition (01-05-2006)
    “…Previous investigations of solid organ transplant patients treated with tacrolimus showed that individuals carrying a CYP3A5*1 allele have lower dose-adjusted…”
    Get full text
    Journal Article
  15. 15

    Genetic Risk Factors for Major Bleeding in Patients Treated With Warfarin in a Community Setting by Roth, J A, Boudreau, D, Fujii, M M, Farin, F M, Rettie, A E, Thummel, K E, Veenstra, D L

    Published in Clinical pharmacology and therapeutics (01-06-2014)
    “…The influence of warfarin pharmacogenomics on major bleeding risk has been little studied in long‐term users and non–specialist care settings. We conducted a…”
    Get full text
    Journal Article
  16. 16

    In vitro and in vivo drug interactions involving human CYP3A by Thummel, K E, Wilkinson, G R

    “…Cytochrome P4503A (CYP3A) is importantly involved in the metabolism of many chemically diverse drugs administered to humans. Moreover, its localization in high…”
    Get full text
    Journal Article
  17. 17

    ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION by ISOHERRANEN, Nina, KUNZE, Kent L, ALLEN, Kyle E, NELSON, Wendel L, THUMMEL, Kenneth E

    Published in Drug metabolism and disposition (01-10-2004)
    “…Itraconazole (ITZ) is a potent inhibitor of CYP3A in vivo. However, unbound plasma concentrations of ITZ are much lower than its reported in vitro K i , and no…”
    Get full text
    Journal Article
  18. 18

    Accurate Prediction of Dose‐Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data by Templeton, I, Peng, C‐C, Thummel, K E, Davis, C, Kunze, K L, Isoherranen, N

    Published in Clinical pharmacology and therapeutics (01-10-2010)
    “…Inhibitory drug metabolites may contribute to drug–drug interactions (DDIs). The aim of this study was to determine the importance of inhibitory metabolites of…”
    Get full text
    Journal Article
  19. 19

    Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism by Lin, Yvonne S, Dowling, Amy L S, Quigley, Sean D, Farin, Federico M, Zhang, Jiong, Lamba, Jatinder, Schuetz, Erin G, Thummel, Kenneth E

    Published in Molecular pharmacology (01-07-2002)
    “…We recently demonstrated that a variant allele of CYP3A5 (CYP3A5*3) confers low CYP3A5 expression as a result of improper mRNA splicing. In this study, we…”
    Get more information
    Journal Article
  20. 20

    Ethical Issues in Developing Pharmacogenetic Research Partnerships With American Indigenous Communities by Boyer, BB, Dillard, D, Woodahl, EL, Whitener, R, Thummel, KE, Burke, W

    Published in Clinical pharmacology and therapeutics (01-03-2011)
    “…Pharmacogenetic research offers the potential to improve the safety and efficacy of drug prescribing. Assuring that the benefits of this research reach…”
    Get full text
    Journal Article